Management of pregnancies complicated by anti-Fy(a) alloimmunization.
BACKGROUND
The objective was to evaluate the management and outcome of patients with anti-Fy(a) at the Ohio State University.


METHODS
A database search for patients with pregnancies complicated only by anti-Fy(a) from 1959 to 2004. Collected information included maternal testing, fetal therapy, and neonatal outcomes.


RESULTS
The final data set included 18 pregnancies in 15 women where anti-Fy(a) was the only maternal alloantibody present and the fetus was Fy(a) antigen-positive. Maternal antibody titers of at least 32 and optical density at 450 nm values in modified Liley Zone IIB or III identified all fetuses or neonates with significant hemolytic disease (2/18, 11%). No fetuses had hydrops, and there were no deaths attributed to hemolytic disease of the fetus and newborn.


CONCLUSIONS
Anti-Fy(a) has the potential to lead to significant fetal hemolysis. Management guidelines developed for D sensitization are appropriate for pregnancies complicated by anti-Fy(a) alloimmunization.
Hughes
Laura H
LH
Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Ohio State University College of Medicine and Public Health, Columbus, OH 43210, USA.
Rossi
Karen Q
KQ
Krugh
David W
DW
O'Shaughnessy
Richard W
RW
D000328:Adult; D004375:Duffy Blood-Group System / Q000276:immunology*; D005078:Exchange Transfusion, Whole Blood; D005260:Female; D005865:Gestational Age; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007231:Infant, Newborn; D007519:Isoantigens / Q000276:immunology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology*; D011956:Receptors, Cell Surface / Q000276:immunology*; D012189:Retrospective Studies
C473745:ACKR1 protein, human; D004375:Duffy Blood-Group System; D006454:Hemoglobins; D007519:Isoantigens; D011956:Receptors, Cell Surface